Veozah in Your 30s: Should You Take It?

What Is Veozah and Why Are Women in Their 30s Asking About It?

Veozah (fezolinetant) is a non-hormonal prescription drug that blocks the neurokinin 3 (NK3) receptor in the hypothalamus, reducing the neuronal firing that triggers hot flashes and night sweats. The FDA approved fezolinetant in May 2023 specifically for moderate-to-severe vasomotor symptoms (VMS) caused by menopause. It does not contain estrogen or progestogen, which is part of why it has attracted attention from women who cannot or prefer not to use hormone therapy.

Women in their 30s are searching for this drug for understandable reasons. If you are 34 and having drenching night sweats, you want answers, not a dismissal. But the age range of 30 to 39 covers enormously different hormonal territory, from peak reproductive years to early perimenopause to the aftermath of a bilateral oophorectomy. Where you fall on that spectrum shapes whether fezolinetant is appropriate for you at all.

The drug's prescribing population in clinical trials skewed older. The SKYLIGHT 1 and SKYLIGHT 2 key trials enrolled postmenopausal women with a mean age of approximately 53 years, and the FDA label carries no pediatric or reproductive-age-specific dosing data. That is a meaningful evidence gap, and you deserve to know it.

How Fezolinetant Works: The NK3 Pathway and Your Hormones

Understanding the mechanism helps you see why this drug sits at an intersection of neuroscience and reproductive endocrinology.

The KNDy Neuron Connection

In the hypothalamus, a cluster of neurons called KNDy neurons (kisspeptin, neurokinin B, dynorphin) regulate the release of gonadotropin-releasing hormone (GnRH) and, by extension, LH and FSH. During the menopausal transition, falling estrogen levels remove the inhibitory brake on these neurons. They fire excessively, activating the thermoregulatory center and producing the characteristic hot flash. Research published in Menopause describes this pathway in detail and explains why NK3 receptor blockade is pharmacologically logical.

Why Hormonal Status in Your 30s Matters for This Mechanism

Here is the clinically important point for younger women: the NK3 pathway becomes dysregulated primarily because of estrogen withdrawal. If you are in your mid-30s with regular cycles and normal estrogen levels, your KNDy neurons are not firing excessively in the same way. Hot flashes experienced during regular menstrual cycles may have other causes, including anxiety, thyroid dysfunction, or paraneoplastic syndromes, and fezolinetant is not the appropriate treatment for those.

If you are 37 with a history of bilateral oophorectomy, you have surgical menopause. Your estrogen dropped abruptly and your KNDy neurons are behaving exactly as they do in a 54-year-old postmenopausal woman. The pharmacology applies. ACOG Practice Bulletin No. 141 on management of menopausal symptoms notes that women with surgical menopause often experience more severe VMS than those with natural menopause, because estrogen loss is sudden rather than gradual.

Who in Their 30s Might Actually Qualify for Veozah?

Most women in their 30s will not qualify. That is not a gatekeeping statement. It is a safety and efficacy statement. Fezolinetant is indicated for VMS of menopause, which requires confirmed menopause or menopausal transition.

Premature Ovarian Insufficiency (POI)

Premature ovarian insufficiency affects approximately 1% of women under age 40. Women with POI experience irregular or absent periods, elevated FSH, low estradiol, and often severe VMS. If you have a confirmed POI diagnosis and your provider has already established that estrogen therapy is contraindicated or not your preference, fezolinetant may be a reasonable non-hormonal option for VMS control. The evidence base here is extrapolated from postmenopausal trial data, not trials in women with POI specifically. That is an honest limitation.

Surgical Menopause from Oophorectomy

Bilateral oophorectomy before natural menopause creates an immediate, complete estrogen deficiency. Women who have undergone this procedure for endometriosis, ovarian cancer risk reduction (including BRCA1/2 carriers), or other reasons may be in their early 30s when their VMS begin. This is one of the clearest qualifying scenarios for fezolinetant in younger women, provided fertility is no longer a goal and pregnancy risk is managed.

Early or Late Perimenopause With Severe VMS

Perimenopause can begin in the mid-to-late 30s for some women, particularly those with a family history of early menopause. If your cycles have become irregular and you are experiencing bothersome vasomotor symptoms confirmed to be related to ovarian aging, your provider may consider fezolinetant. The Menopause Society 2023 position statement on non-hormonal management of VMS lists fezolinetant as an effective non-hormonal option for women with moderate-to-severe VMS.

Chemotherapy-Induced or Treatment-Related Menopause

Women in their 30s who have received chemotherapy for breast cancer or other cancers may experience treatment-related ovarian failure. Fezolinetant is particularly relevant here because it is non-hormonal and is not thought to stimulate estrogen-sensitive tissues. However, evidence in women with hormone-receptor-positive breast cancer receiving endocrine therapy is limited, and the FDA label does not address this population specifically. Discuss with your oncologist before starting.

Who in Their 30s Should Not Take Veozah?

Women who are pregnant, trying to conceive, or currently breastfeeding should not take fezolinetant. Women with cirrhosis or severe hepatic impairment are contraindicated. Women taking strong CYP1A2 inhibitors, including fluvoxamine, are contraindicated because fezolinetant is metabolized predominantly by CYP1A2, and inhibition raises plasma levels substantially.

Women with regular menstrual cycles, no diagnosis of POI or early perimenopause, and hot flashes attributed to other causes are not candidates for this drug. Off-label use in reproductive-age women with normal ovarian function has not been studied for safety or efficacy.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting

This section is required reading if you are in your 30s and taking or considering fezolinetant.

Pregnancy: An Absolute Contraindication

Fezolinetant is contraindicated in pregnancy. The FDA prescribing information states that the drug should be discontinued immediately if pregnancy is confirmed. Animal reproductive toxicity data showed adverse developmental effects at clinically relevant exposures, though controlled human pregnancy data do not exist. Because the drug is given in the context of menopausal symptoms, the label assumes the patient is not pregnant. For women in their 30s who may still have residual or intermittent ovarian function, including those in perimenopause or those with POI who experience occasional ovulatory cycles, this assumption does not hold automatically.

Women with POI have an approximately 5% chance of spontaneous pregnancy. That number is not zero.

Contraception Requirements

Because spontaneous ovulation remains possible in some women taking fezolinetant in their 30s, reliable contraception is mandatory for any woman who has not had a surgical procedure that confirms sterility or who has not been confirmed to be fully post-menopausal by laboratory and clinical criteria. Non-hormonal contraceptive options, including copper IUDs, condoms, or tubal ligation, are preferable for women who wish to avoid adding exogenous hormones. Talk with your provider about what combination makes sense for your situation.

Lactation

No human data exist on fezolinetant transfer into breast milk. The FDA label advises against use during breastfeeding because of the lack of safety data and the potential for adverse effects in a nursing infant. If you are postpartum and breastfeeding in your 30s and experiencing vasomotor symptoms, which can occur during lactational amenorrhea, speak with your provider about timing and alternatives. Postpartum hot flashes are common and typically resolve with the return of menstrual function; they do not require fezolinetant.

The SKYLIGHT Trials: What the Evidence Actually Shows

The two key phase 3 trials, SKYLIGHT 1 and SKYLIGHT 2, randomized postmenopausal women with at least seven moderate-to-severe hot flashes per day to fezolinetant 30 mg, fezolinetant 45 mg, or placebo once daily. At 12 weeks, the 45 mg dose reduced the frequency of moderate-to-severe hot flashes by approximately 59% compared to a 34% reduction with placebo.

Three points matter specifically for women in their 30s reading this:

First, the enrolled population was postmenopausal with a mean age around 53. Younger women, women in perimenopause, and women with POI were not enrolled in meaningful numbers. The evidence is being applied to your demographic by clinical extrapolation, not by direct study.

Second, the trial did include SKYLIGHT 4, a 52-week safety extension, which found no increase in endometrial hyperplasia or malignancy in participants. This is reassuring for the uterus but does not provide reproductive-age-specific safety data.

Third, women were required to be in natural or surgical menopause to enroll. If you have irregular cycles but have not met the clinical definition of menopause, your situation falls outside the studied population.

Dosing in Your 30s: Is It Any Different?

The approved dose of fezolinetant is 45 mg once daily by mouth, with no food requirement. The pharmacokinetics do not appear to differ substantially by age within the adult range studied in trials, but no dedicated pharmacokinetic study in women under 40 has been published. Women with moderate hepatic impairment require dose adjustment; women with severe hepatic impairment should not take the drug.

Body weight and body composition differences in younger women have not been studied as fezolinetant dose modifiers. No dose adjustment for BMI is specified in the label. This is an area where more sex-specific and age-specific data would be useful.

Liver Function Monitoring: Do Not Skip This Step

Fezolinetant has been associated with hepatocellular injury in a small number of patients in post-marketing reports. The FDA label requires:

• Baseline liver function tests (LFTs) before starting
• LFTs at 3 months
• LFTs at 6 months

If ALT or AST rises above five times the upper limit of normal, fezolinetant should be discontinued. For women in their 30s who may be on other medications affecting the liver, including azole antifungals for recurrent yeast infections or certain hormonal therapies, flag all your medications to your provider before the first prescription is written.

Fezolinetant and PCOS: Is There a Role?

This question comes up because many women with PCOS are in their 30s, some experience hot flashes as part of their hormonal dysregulation, and PCOS is associated with altered LH pulsatility. The NK3/KNDy pathway is involved in GnRH and LH regulation broadly, not only in the menopausal context.

Research in animal models and small human studies has explored NK3 receptor antagonism as a way to reduce LH hypersecretion in PCOS. A 2018 study in the Journal of Clinical Endocrinology and Metabolism found that NK3 receptor blockade reduced LH pulse frequency in women with PCOS. This is genuinely interesting pharmacology.

However, fezolinetant is not approved for PCOS. No adequately powered clinical trial has established safety or efficacy for PCOS management specifically. Using fezolinetant off-label for PCOS in a woman who is trying to conceive would be particularly inappropriate given the pregnancy contraindication. This is an active research area, but the clinical evidence is not yet at a level that supports routine use.

How Fezolinetant Fits Alongside Hormone Therapy and Other Options

If you are in your 30s with surgical menopause or POI and you cannot use or do not want estrogen therapy, fezolinetant is one of the few non-hormonal options with solid phase 3 trial data specifically for VMS. The Menopause Society 2023 non-hormonal position statement ranks fezolinetant as one of the most effective non-hormonal interventions available, alongside cognitive behavioral therapy and clinical hypnosis for VMS reduction.

For context on what you are comparing against: the SSRIs and SNRIs (paroxetine, escitalopram, venlafaxine) and gabapentin have been used off-label for VMS with modest efficacy, reducing hot flash frequency by roughly 30 to 60% in various trials. Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal option for VMS before fezolinetant. Fezolinetant's approximately 59% frequency reduction at 12 weeks makes it the most effective non-hormonal option currently approved.

If you do want hormone therapy and your provider agrees it is appropriate for your situation, estrogen therapy remains the most effective treatment for VMS. Fezolinetant is not a replacement for HRT in women who are good candidates for it. It is an alternative for those who are not.

What Your 30s Hormonal Field Means for Side Effects

The most common adverse effects reported in trials were abdominal pain (reported in approximately 9% of fezolinetant patients versus 4% of placebo), diarrhea, and insomnia. Hot flash rebound on discontinuation has been reported anecdotally, though it was not a primary endpoint in trials.

For women in their 30s with perimenopausal hormonal fluctuations, teasing apart drug side effects from fluctuating estrogen symptoms can be tricky. Keep a symptom diary during the first 12 weeks. If your GI symptoms are significant and persistent, report them. Abdominal pain that is severe should prompt LFT re-evaluation even before the scheduled 3-month check.

Women in their 30s are also more likely than older women to be on oral contraceptives, which can affect CYP1A2 activity depending on formulation, and to be managing other conditions with polypharmacy. A comprehensive medication review before starting fezolinetant is not optional. It is part of safe prescribing.

Talking to Your Provider: What to Bring to the Appointment

Bring documentation of your menstrual cycle pattern over the past 6 to 12 months, any FSH/estradiol labs, and a complete medication and supplement list. If your provider has not checked thyroid function recently, ask for it. Thyroid dysfunction is a common cause of heat intolerance and flushing in women in their 30s and should be excluded before attributing your symptoms to VMS.

Ask directly: "Does my hormonal status meet the indication for fezolinetant?" If your FSH is in the menopausal range (typically above 40 IU/L on more than one occasion, at least 4 to 6 weeks apart, with amenorrhea) and your clinical picture fits, your provider can make that determination.

If your provider is hesitant because of your age, that hesitancy is clinically reasonable, not dismissive. The evidence base for this drug in women under 40 is thin. A referral to a reproductive endocrinologist or a menopause specialist for complex cases is appropriate and worth asking for.